Seems you have not registered as a member of localhost.saystem.shop!
You may have to register before you can download all our books and magazines, click the sign up button below to create a free account.
Chrysomeloidea II (Orsodacnidae, Megalopodidae, Chrysomelidae) – Part 2
Volume 6/2 of the Catalogue of Palaearctic Coleoptera focuses on the second part of the beetle superfamily Chrysomeloidea reported from the Palaearctic biogeographic region. For the genus and species-groups taxa all relevant names are given and all nomenclatural data are cross-checked and the distribution of species and subspecies is given per country or smaller region. A group of 14 experts have worked to collect data based on a critical review of published sources including a significant amount of new information. This volume is also a tool for specialists as well as amateurs, which warrants unambiguous communication.
Toxicologic Pathology
Following the success of the first edition, this book is designed to provide practical and timely information for toxicologic pathologists working in pharmaceutical drug discovery and development. The majority of the book (Organ Systems) will provide detailed descriptions of histopathological lesions observed in drug development. In addition, it will provide information to assist the pathologist in making determinations of the origin of lesions as well as its relevance to human risk. Toxicologic Pathology: Nonclinical Safety Assessment, Second Edition includes 2 new concept chapters. The first of the new chapters address approaches for the evaluation of unique therapeutic modalities such as ...
Development of Gene Therapies
Cell and gene therapies have become the third major drug modality in pharmaceutical medicine of the 21st century after low molecular weight and antibody drugs. The gene therapy (GTx) field is rapidly advancing, and yet there are still fundamental scientific questions that remain to be answered. Development of GTx products poses unique challenges and opportunities for drug developers. However, there is lack of a systematic exposition of the GTx product development and the pivotal role of the biostatistician in this process. Development of Gene Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, s...
Vaccinations: a History
This English language edition is far more than a simple translation of the work "L'Histoire des vaccinations" published in 2008 in the same collection. The French edition has actually been totally revised and improved. In particular, it features a chapter dedicated entirely to yellow fever. A greater number of illustrations are included. This book will undoubtedly be of great interest to a section of the general public and to specialists. The history of vaccinations is a significant phase in the history of humanity. With the development of hygiene, vaccinations have certainly been the most notable progress of medicine. Nevertheless, this subject which has revolutionised human and animal medicine has long been explored poorly or not at all. This oversight has now been addressed through this fascinating work. All translated Pasteur texts are from the original manuscripts found in his laboratory notebooks. Finally, the moral problems inherent in the use of vaccines are addressed and at times, appear strangely similar to current situations…
Proteasome Inhibitors in Cancer Therapy
A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (VelcadeTM) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.
